Department of Orthopedic Surgery, University of California, Irvine, Orange, CA, USA.
Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, USA.
Cartilage. 2021 Dec;13(1_suppl):262S-270S. doi: 10.1177/19476035211060512. Epub 2021 Nov 20.
Meniscus tissue deficiency resulting from primary meniscectomy or meniscectomy after failed repair is a clinical challenge because the meniscus has little to no capacity for regeneration. Loss of meniscus tissue has been associated with early-onset knee osteoarthritis due to an increase in joint contact pressures in meniscectomized knees. Clinically available replacement strategies range from allograft transplantation to synthetic implants, including the collagen meniscus implant, ACTIfit, and NUSurface. Although short-term efficacy has been demonstrated with some of these treatments, factors such as long-term durability, chondroprotective efficacy, and return to sport activities in young patients remain unpredictable. Investigations of cell-based and tissue-engineered strategies to treat meniscus tissue deficiency are ongoing.
由于初次半月板切除术或修复失败后的半月板切除术导致的半月板组织缺失是一个临床挑战,因为半月板几乎没有再生能力。由于半月板切除后的膝关节关节接触压力增加,半月板组织的丧失与早发性膝关节骨关节炎有关。临床可用的替代策略范围从同种异体移植到合成植入物,包括胶原半月板植入物、ACTIfit 和 NUSurface。尽管这些治疗中的一些已经显示出短期疗效,但长期耐久性、软骨保护疗效以及年轻患者重返运动活动等因素仍然难以预测。目前正在进行基于细胞和组织工程的策略来治疗半月板组织缺失的研究。